Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral antiseptic for viral load reduction in mild to moderate COVID-19
RBR-58ftdjRecruiting
- Sponsor
- Universidade de São Paulo
- Start
- Aug 2020
- Countries
- 1
01
Overview
Open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Universidade de São Paulo. Primary endpoints: Clinical status improvement, SARS-CoV-2 viral load reduction and 1 more. Started Aug 2020; status: recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-58ftdj.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-58ftdj.